Real‐World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido‐ TZP Study
Authors' conclusion
Tirzepatide demonstrated robust clinical efficacy and a favourable safety profile in a real-world clinical setting, regardless of whether incretin-based therapy had been administered previously.
Study context
- Population
- Subjects with T2D treated with tirzepatide for ≥ 6 months, 10 centres in Hokkaido, Japan; mean age 55.6 ± 12.5 years, mean BMI 30.6 ± 5.8; 81.3% on incretin-based medications at baselineanalysed
- Participants
- 828 subjects
- Outcome
- Changes in HbA1c and other metabolic parameters, alongside adverse events leading to discontinuation of tirzepatide
- Follow-up
- 6 months
Methodological detailsmulticentre, 10 medical centers in Hokkaido, Japan
- Multicentre
- 10 medical centers in Hokkaido, Japan
Main finding
As reported in the abstract
HbA1c change
−1.07%
95% CI −1.16, −0.98; baseline 7.82% ± 1.59%p < 0.001
Body weight change
−3.1 kg
95% CI −3.4, −2.8; baseline 83.8 ± 18.5 kgp < 0.001
Observational data: associations, not effects.
Further findings
- Efficacy consistent in patients switching from incretin-based medications
Safety
Discontinuation of tirzepatide
- Discontinued because of adverse events, personal preference or other clinical reasons
- 45 subjects
Original publication
Real‐World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido‐ TZP Study. Diabetes Obes Metab. Published 7 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →